Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study.
Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia (CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM by evaluating individual patient characteristics, personal behaviour and, treatment related psychological factors influencing adherence behaviour. Hundred patients receiving IM were analysed for adherence behaviour using 9 item Morisky Medication Adherence Scale (9-MMAS). Various factors were assessed for their impact on adherence behaviour. These factors were age, gender, duration of treatment, frequency and dosing of treatment, use of tobacco and alcohol, educational qualification, employment status, monthly income, side effects, financial assistance in treatment, social support, knowledge about medicine and disease, concomitant drug burden, polypharmacy, physician patient interaction, patient educational sessions and prevalence of depression. Seventy five percent of patients were found to be adherent. On univariate analysis, prevalence of depression (p<0.000001), moderate severe depression (p<0.000001), concomitant drug burden (p=0.036) and monthly income (p=0.015) were found to be significantly influencing adherence. The final multivariate model retained prevalence of depression with OR= 10.367 (95% CI, 3.112-34.538) as independent predictor of adherence to therapy. This study suggests that identification and treatment of depression among CML patients may further enhance adherence to IM therapy.
Masters in Clinical Research, Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, Delhi, India. PIN 110085.
Jyotsna
J
Kapoor
DM, Consultant Hematology, Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, Delhi, India. PIN 110085.
Narendra
N
Agrawal
DM, Consultant Hematology, Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, Delhi, India. PIN 110085.
Rayaz
R
Ahmed
DM, Consultant Hematology, Hemato-Oncology and BMT Unit, BLK Superspeciality Hospital, Rajendra Place, New Delhi, India, PIN 110008.
Sanjeev Kumar
SK
Sharma
DM, Consultant Hematology, Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, Delhi, India. PIN 110085.
Anshul
A
Gupta
DM, Consultant Hematology, Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, Delhi, India. PIN 110085.
Dinesh
D
Bhurani